| Biomarker ID | 825 |
| PMID | 22142399 |
| Year | 2011 |
| Biomarker | CRISP3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in TMPRSS2-ERG gene fusion (37 fold) compared to benign samples, normal and fusion-negative tumor samples (FC = 1.2) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Innate Immune System |
| Experiment | Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion |
| Type of Biomarker | Diagnostic |
| Cohort | 48 prostate tissue samples were chosen out of which 37 were further selected such that 17 had TMPRSS2-ERG gene fusion and 20 did not. Validation cohort 29 benign and 72 fusion-negative and 48 fusion-positive tumor samples. GEO Accession: GSE29079. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | TMPRSS2-ERG positive tumors compared to normal tissue (p = 2.2*10-12), normal and fusion-negative tumor samples (p = 0.03) |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | CRISP3 |